4. April 2016 von

Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo

Novo Nordisk A/S: Boston (ots/PRNewswire) – For non-US medical media only. For journalistic assessment and preparation before publication. Oral Presentation# OR36-1 Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical …

Comments are closed.